secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001935979-24-000086
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024
--------------------------------------------------------------------------------

- Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).
- Cash position $642M as of Oct 2, 2024, including $269.9M net from Oct 2024 public offering of 6.05M shares at $47.50.
- Troriluzole met primary endpoint in pivotal SCA trial; NDA submission to FDA on track for Q4 2024.
- Initiated Phase 2 trial of BHV-2100 (TRPM3 antagonist) in acute migraine; expects Phase 3 SMA topline data in Q4 2024.
- R&D expenses rose to $157.6M from $95.5M YoY due to advancing late-stage trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/0001935979-24-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597924000086/bhvn-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001935979-24-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer